The global spinal cord injury (SCI) therapeutics market is projected to reach $7.5B by 2030 (Grand View Research), yet no approved disease-modifying treatments exist beyond supportive care. A collaboration between China Medical University Hospital (CMUH), Ever Supreme International Biotechnology, and SHINE OUT BIO TECHNOLOGY has unveiled a novel exosome-based platform that delivers BDNF mRNA directly to lesion sites via intravenous injection, demonstrating motor coordination improvements in preclinical models.
The platform leverages exosomes engineered with targeting ligands for spinal cord homing, encapsulating mRNA encoding brain-derived neurotrophic factor (BDNF). This approach avoids invasive intrathecal injections required by many cell and gene therapies. In rodent contusion models, treated animals showed statistically significant improvements in Basso-Beattie-Bresnahan (BBB) locomotor scores compared to controls (data not yet peer-reviewed).
Competing approaches in SCI include Neuralstem's NSI-566 (stem cell therapy, Phase II), Asterias' AST-OPC1 (oligodendrocyte progenitors, Phase I/IIa), and Kringle Pharma's KP-100 (hepatocyte growth factor, Phase II). None have achieved FDA approval. The exosome platform's key differentiator is non-invasive IV delivery, potentially reducing infection risk and enabling repeat dosing. However, exosome manufacturing scalability and mRNA stability remain challenges.
For investors, the platform's versatility extends beyond SCI: BDNF mRNA delivery could address neurodegenerative diseases (ALS, Alzheimer's) and peripheral nerve injuries. The partners plan to advance to IND-enabling studies within 12 months. No financial terms were disclosed, but the asset is early-stage with significant technical risk.
